The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II trial of enzalutamide (Enz) with 5-alpha reductase inhibitors (5-ARI) as an androgen deprivation therapy (ADT)–sparing approach for older men with castration-sensitive prostate cancer (CSPC).
 
Deepak Kilari
Honoraria - Exelixis
Consulting or Advisory Role - Exelixis; Merck Sharp & Dohme; Pfizer
Speakers' Bureau - Astellas Pharma; AVEO; Exelixis; Janssen
Research Funding - Astellas Pharma (Inst); Exelixis (Inst); Genentech (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AVEO; Exelixis; Janssen
 
Sindhuja G Kadambi
No Relationships to Disclose
 
Andrea M. Baran
No Relationships to Disclose
 
Jason Zittel
No Relationships to Disclose
 
John D. Burfeind
No Relationships to Disclose
 
Edward M. Messing
No Relationships to Disclose
 
Peter J. Van Veldhuizen
No Relationships to Disclose
 
Kathryn A. Bylow
No Relationships to Disclose
 
Deepak M. Sahasrabudhe
No Relationships to Disclose
 
Supriya Gupta Mohile
No Relationships to Disclose
 
Chunkit Fung
Consulting or Advisory Role - Exelixis; Novartis; Novartis
Research Funding - Astellas Pharma (Inst)